Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.

Waller, Cornelius F; Möbius, Julia; Fuentes-Alburo, Adolfo

Waller, Cornelius F; Möbius, Julia; Fuentes-Alburo, Adolfo.

Affiliation

Waller CF; Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany. cornelius.waller@uniklinik-freiburg.de.
Möbius J; Mylan Healthcare GmbH, Hannover, Germany.
Fuentes-Alburo A; Mylan Inc., Canonsburg, PA, USA.

Br J Cancer ; 124(8): 1346-1352, 2021 04.

Article in En | MEDLINE | ID: mdl-33589773

Subject(s)

Biosimilar Pharmaceuticals/administration & dosage; Breast Neoplasms/drug therapy; Trastuzumab/administration & dosage; Administration, Intravenous/economics; Biosimilar Pharmaceuticals/economics; Breast Neoplasms/genetics; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Injections, Subcutaneous/economics; Receptor, ErbB-2/genetics; Trastuzumab/economics; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Biosimilar Pharmaceuticals / Trastuzumab Limits: Female / Humans Language: En Journal: Br J Cancer Year: 2021 Type: Article Affiliation country: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google